GSK reported strong financial performance with significant growth in Specialty Medicines and vaccines. However, challenges in supply chain costs, regulatory delays for Blenrep, and difficulties in the Chinese market were notable concerns.

Company Guidance

In the GSK Q2 2025 Results Call, the company reported a strong performance with group sales up by 6% and core operating profit increasing by 12%. Core earnings per share grew 15% to 46.5p. Specialty Medicines, the largest segment, showed robust growth of 15%, while vaccines also contributed with a 9% sales increase. The company has achieved three FDA approvals this year, maintaining a positive cash generation of GBP 3.7 billion in the first half. A dividend of 16p was declared, and over GBP 800 million worth of shares have been bought back since February. GSK is progressing towards the top end of its 2025 financial guidance, driven by investments in 14 major scale opportunities with expected peak year sales above GBP 2 billion. The company aims for Specialty Medicines to account for over 50% of sales by 2031.

Strong Financial Performance

Group sales increased by 6% for the quarter, core operating profit rose by 12%, and core earnings per share grew by 15% to 46.5p. Specialty Medicines sales were up 15%, and vaccine sales increased by 9%.

R&D Achievements

Three FDA approvals were achieved so far this year. The company is making progress in R&D with several pivotal trial readouts and new high-potential assets entering late-stage development.

Positive Cash Flow and Shareholder Returns

Cash generation remains strong with GBP 3.7 billion generated in the first half. More than GBP 800 million of the share buyback program has been completed, and the dividend for the quarter was 16p.

Guidance Update

GSK now expects to be towards the top end of the financial guidance given for 2025, reflecting strong performance momentum.

GlaxoSmithKline (GSK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GSK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	1.24 / -	1.293	―	―	―
Jul 30, 2025	2025 (Q2)	1.17 / 1.24	1.115	10.85% (+0.12)
Apr 30, 2025	2025 (Q1)	1.04 / 1.20	1.077	11.33% (+0.12)
Feb 05, 2025	2024 (Q4)	0.49 / 0.58	0.736	-21.06% (-0.16)
Oct 30, 2024	2024 (Q3)	1.15 / 1.29	1.222	5.81% (+0.07)
Jul 31, 2024	2024 (Q2)	0.98 / 1.11	1.003	11.17% (+0.11)
May 01, 2024	2024 (Q1)	0.92 / 1.08	0.923	16.68% (+0.15)
Jan 31, 2024	2023 (Q4)	0.74 / 0.74	0.636	15.72% (+0.10)
Nov 01, 2023	2023 (Q3)	1.11 / 1.22	1.075	13.67% (+0.15)
Jul 26, 2023	2023 (Q2)	0.89 / 1.00	0.835	20.12% (+0.17)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GSK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$37.27	$38.55	+3.43%
Apr 30, 2025	$38.11	$38.97	+2.26%
Feb 05, 2025	$33.70	$36.47	+8.22%
Oct 30, 2024	$36.53	$35.42	-3.04%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.